Skip to Content

16,979 Results Found

  • Article
  • Open Access
65 Citations
1,829 Views
10 Pages

1 February 2011

Urothelial cancer of the bladder is the 4th most common malignancy in American men and the 9th most common in women. Although it is a chemosensitive disease, advanced bladder cancer seems to have reached a plateau with regard to median survival of pa...

  • Review
  • Open Access
15 Citations
4,956 Views
14 Pages

Immunotherapy in the First-Line Setting in Wild-Type NSCLC

  • Marie-Hélène Denault and
  • Barbara Melosky

3 November 2021

Treatment algorithms in the treatment of advanced non-small cell lung cancer (NSCLC) continue to evolve as new therapeutics show positive efficacy improvements. This review article summarizes the data for the use of immunotherapy for treatment in fir...

(This article belongs to the Special Issue Current State of Immunotherapy for Lung Cancer)
  • Article
  • Open Access
33 Views
10 Pages

15 November 2026

Background/Objectives: Psoriasis is a common chronic inflammatory skin disorder, affecting approximately 0.6–1.1% of adults worldwide. Guselkumab, a selective interleukin (IL)-23 inhibitor, is highly effective in moderate-to-severe plaque psori...

(This article belongs to the Special Issue Autoimmune Skin Diseases: Innovations, Challenges, and Opportunities)
  • Article
  • Open Access
1 Citations
4,893 Views
15 Pages

Two-Year Outcome of Selective Laser Trabeculoplasty for Normal-Tension Glaucoma in Japan: First-Line or Second-Line Selective Laser Trabeculoplasty (FSS) Study

  • Tomoko Naito,
  • Koji Nitta,
  • Takako Miki,
  • Akiko Narita and ,
  • Tairo Kimura,
  • Yasushi Ikuno,
  • Shiro Mizoue,
  • Maki Katai,
  • Yoshiaki Saito and
  • Masaki Tanito
  • + 33 authors+ 28 authors

15 May 2025

Objectives: The objective of this study is to investigate the two-year continuous efficacy, risk factors, and safety profile of selective laser trabeculoplasty (SLT) in Japanese individuals diagnosed with normal-tension glaucoma (NTG) who underwent S...

(This article belongs to the Section Ophthalmology)
  • Article
  • Open Access
25 Citations
6,664 Views
15 Pages

European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain

  • María Caldas,
  • Ángeles Pérez-Aisa,
  • Manuel Castro-Fernández,
  • Luis Bujanda and ,
  • Alfredo J. Lucendo,
  • Luis Rodrigo,
  • Jose M. Huguet,
  • Jorge Pérez-Lasala,
  • Javier Molina-Infante and
  • Javier P. Gisbert
  • + 45 authors+ 40 authors

The management of Helicobacter pylori infection has to rely on previous local effectiveness due to the geographical variability of antibiotic resistance. The aim of this study was to evaluate the effectiveness of first and second-line H. pylori treat...

(This article belongs to the Special Issue Helicobacter pylori: Antibiotic Resistance and Treatment)
  • Brief Report
  • Open Access
1,509 Views
10 Pages

Treatment Sequencing and Independent Outcomes of First- and Second-Line Chemotherapy in a Retrospective Series of Patients with Biliary Tract Cancer

  • Giorgio Frega,
  • Andrea Palloni,
  • Chiara Deiana,
  • Alessandro Rizzo and ,
  • Angela Dalia Ricci and
  • Giovanni Brandi
  • + 1 author+ 0 author

29 November 2024

Background/Objectives: Biliary tract cancers (BTCs) are aggressive neoplasms with limited therapeutic options. The amount of prospective evidence is poor, and limited data are available on the impact of treatment sequencing on survival. Here we repor...

(This article belongs to the Section Oncology)
  • Article
  • Open Access
14 Citations
3,773 Views
18 Pages

First-Line Immunotherapy with Check-Point Inhibitors: Prospective Assessment of Cognitive Function

  • Jamie S. Myers,
  • Adam C. Parks,
  • Jonathan D. Mahnken,
  • Kate J. Young and ,
  • Harsh B. Pathak,
  • Rajni V. Puri,
  • Amber Unrein,
  • Phyllis Switzer,
  • Yazan Abdulateef and
  • Jeffrey M. Burns
  • + 8 authors+ 3 authors

6 March 2023

Approximately 40% of patients with cancer are eligible for check-point inhibitor (CPI) therapy. Little research has examined the potential cognitive impact of CPIs. First-line CPI therapy offers a unique research opportunity without chemotherapy-rela...

(This article belongs to the Special Issue Cognitive Outcomes in Cancer: Recent Advances and Challenges)
  • Systematic Review
  • Open Access
10 Citations
3,422 Views
13 Pages

20 July 2024

Introduction: There is a significant gap in the literature concerning the effective management of second-line therapy for patients with metastatic renal cell carcinoma (RCC) who have received immune checkpoint inhibitors (ICIs). Most of the published...

(This article belongs to the Special Issue Advances in Drug Delivery for Cancer Therapy)
  • Article
  • Open Access
1 Citations
829 Views
18 Pages

Prognostic Significance of Inflammatory Biomarkers in First-Line Immunotherapy for Metastatic Melanoma: Multicentric Study

  • Branko Dujovic,
  • Aleksandar Popovic,
  • Amina Jalovcic Suljevic,
  • Bojana Cikota-Aleksic and ,
  • Mirjana Balic,
  • Igor Salatic,
  • Jovana Pavlica,
  • Philipp Schnecko,
  • Tanja Mesti and
  • Lidija Kandolf
  • + 7 authors+ 2 authors

25 May 2026

Background/Objectives: This study evaluates the prognostic value of baseline inflammatory biomarkers, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), lymphocyte-to-monocyte ratio (LMR), sy...

(This article belongs to the Section Cancer Biomarkers)
  • Systematic Review
  • Open Access
1 Citations
3,992 Views
16 Pages

21 January 2026

Background: Leiomyosarcomas are an aggressive soft-tissue sarcoma that arise from smooth muscle, have a high metastatic potential and account for 10–20% of soft-tissue sarcomas. Despite decades of research, the first-line treatment remains unre...

(This article belongs to the Special Issue News and How Much to Improve in Management of Soft Tissue Sarcomas)
  • Review
  • Open Access
14 Citations
6,780 Views
28 Pages

Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma

  • Theodoros P. Vassilakopoulos,
  • Athanasios Liaskas,
  • Patricio Pereyra,
  • Panayiotis Panayiotidis and ,
  • Maria K. Angelopoulou and
  • Andrea Gallamini
  • + 1 author+ 0 author

24 August 2023

The long-term survival of Hodgkin lymphoma (HL) patients treated according to the current standard of care is excellent. Combined-modality schedules (ABVD plus radiotherapy) in early-stage disease, along with treatment intensity adaptation to early m...

(This article belongs to the Section Molecular Immunology)
  • Article
  • Open Access
19 Citations
4,089 Views
13 Pages

Pre-Treatment HIV Drug Resistance and Genetic Diversity in Cameroon: Implications for First-Line Regimens

  • Joseph Fokam,
  • Collins Ambe Chenwi,
  • Valère Tala,
  • Désiré Takou and ,
  • Maria Mercedes Santoro,
  • George Teto,
  • Beatrice Dambaya,
  • Felix Anubodem,
  • Ezechiel Ngoufack Jagni Semengue and
  • Alexis Ndjolo
  • + 17 authors+ 12 authors

28 June 2023

The efficacy of first-line antiretroviral therapy (ART) may be hampered by the presence of HIV drug resistance (HIVDR). We described HIV-1 pre-treatment drug resistance (PDR) patterns, effect of viral clades on PDR, and programmatic implications on f...

(This article belongs to the Section Human Virology and Viral Diseases)
  • Article
  • Open Access
2 Citations
1,811 Views
14 Pages

Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis

  • Baris Koksal,
  • Hasan Cagri Yildirim,
  • Deniz Can Guven,
  • Fatih Kose and ,
  • Gorkem Koymen,
  • Ozlem Ozdemir,
  • Ugur Ozberk,
  • Efnan Algin,
  • Murad Guliyev and
  • Zafer Arik
  • + 52 authors+ 47 authors

22 February 2026

Background: Poly(ADP-ribose) polymerase (PARP) inhibitors have been established as a first-line maintenance therapy in advanced epithelial ovarian cancer (EOC) following platinum-based chemotherapy. While phase III trials have demonstrated significan...

(This article belongs to the Section Oncology)
  • Review
  • Open Access
7 Citations
4,205 Views
13 Pages

Tumors include a heterogeneous population, of which a small proportion includes drug-resistant cancer (stem) cells. In drug-sensitive cancer populations, first-line chemotherapy reduces tumor volume via apoptosis. However, it stimulates drug-resistan...

(This article belongs to the Special Issue Contribution of Cancer-Targeting Drugs toward Faster Clinical Application 2.0)
  • Review
  • Open Access
4 Citations
3,888 Views
18 Pages

Refining Criteria for Choosing the First-Line Treatment for Real-World Patients with Advanced ALK-Rearranged NSCLC

  • Edyta Maria Urbanska,
  • Peter Rindom Koffeldt,
  • Morten Grauslund,
  • Linea Cecilie Melchior and ,
  • Jens Benn Sørensen and
  • Eric Santoni-Rugiu
  • + 1 author+ 0 author

Choosing the optimal first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangements can be challenging in daily practice. Although clinical trials with next-generation ALK-tyros...

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
  • Review
  • Open Access
14 Citations
8,675 Views
36 Pages

Sequential versus Standard Triple Therapy for First-Line Helicobacter pylori Eradication: An Update

  • Olga P. Nyssen,
  • Belén Martínez,
  • Francis Mégraud,
  • Vincenzo Savarino and ,
  • Carlo A. Fallone,
  • Franco Bazzoli and
  • Javier P. Gisbert
  • + 2 authors+ 0 author

Background: non-bismuth sequential therapy (SEQ) was suggested as a first-line anti-Helicobacter pylori treatment alternative to standard triple therapy (STT). Methods: We conducted a systematic review with a meta-analysis of randomized controlled tr...

(This article belongs to the Special Issue Helicobacter pylori Infection and Antibiotic Resistance: The Emerging Eradication Strategies)
  • Review
  • Open Access
20 Citations
7,447 Views
14 Pages

24 May 2021

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) in combination with platinum-based chemotherapy has been for the decade standard of care for the treatment of head and neck squamous cell carcinomas (HNSCC) patien...

(This article belongs to the Special Issue Advances in Head and Neck Squamous Cell Carcinoma (HNSCC))
  • Review
  • Open Access
19 Citations
13,766 Views
21 Pages

26 June 2024

First-line systemic therapy for patients with advanced or metastatic non-small cell lung cancer (NSCLC) has rapidly evolved over the past two decades. First, molecularly targeted therapy for a growing number of gain-of-function molecular targets has...

(This article belongs to the Special Issue Advances in Precision Medicine: Targeting Known and Emerging Oncogenic Targets in Lung Cancer)
  • Article
  • Open Access
1,605 Views
16 Pages

A Comparative Study of Different Biological Drugs in First-Line Therapy in Crohn’s Disease: A Multicenter Descriptive Analysis

  • Andrei Gila,
  • Carmen Monica Preda,
  • Mircea Diculescu,
  • Razvan Matei Bratu and ,
  • Doina Istratescu,
  • Tudor Stroie,
  • Anca Trifan,
  • Alina Tantau,
  • Sandica Bucurica and
  • Cosmin Alexandru Ciora
  • + 10 authors+ 5 authors

Background and Objectives: Biologic agents have emerged as the most important therapeutic weapon in the treatment of Crohn’s disease (CD). The aim of this study is to describe the population of patients who received different molecules as first...

(This article belongs to the Special Issue New Advances in Inflammatory Bowel Disease and Diarrheal Disorders)
  • Review
  • Open Access
10 Citations
5,104 Views
14 Pages

Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle

  • Francesca Salani,
  • Virginia Genovesi,
  • Caterina Vivaldi,
  • Valentina Massa and ,
  • Silvia Cesario,
  • Laura Bernardini,
  • Miriam Caccese,
  • Jessica Graziani,
  • Dario Berra and
  • Gianluca Masi
  • + 6 authors+ 1 author

6 October 2022

Immune checkpoint inhibitors (ICIs) are a key component of different stages of hepatocellular carcinoma (HCC) treatment, particularly in the first line of treatment. A lesson on the primary resistance which hampers their efficacy and activity was lea...

(This article belongs to the Special Issue Perspectives of Immunotherapy in Tumors of the Gastrointestinal Tract)
  • Review
  • Open Access
14 Citations
5,470 Views
13 Pages

First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?

  • Yann-Alexandre Vano,
  • Sylvain Ladoire,
  • Réza Elaidi,
  • Slimane Dermeche and ,
  • Jean-Christophe Eymard,
  • Sabrina Falkowski,
  • Marine Gross-Goupil,
  • Gabriel Malouf,
  • Bérangère Narciso and
  • Alain Ravaud
  • + 8 authors+ 3 authors

5 November 2021

The development of antiangiogenic treatments, followed by immune checkpoint inhibitors (ICI), has significantly changed the management of metastatic clear cell renal cell cancer. Several phase III trials show the superiority of combination therapy, d...

(This article belongs to the Special Issue Clear Cell Renal Cell Carcinoma 2021–2022)
  • Article
  • Open Access
3 Citations
2,652 Views
12 Pages

Survival Outcomes Following Combination of First-Line Platinum-Based Chemotherapy with S-1 in Patients with Advanced Gastric Cancer

  • Anna Koumarianou,
  • Anastasios Ntavatzikos,
  • Christos Vallilas,
  • Katerina Kampoli and ,
  • Zoi Kakoseou and
  • Michalis V. Karamouzis
  • + 1 author+ 0 author

15 December 2020

The efficacy of S-1 combined with a platinum agent in the first-line setting and in patients with advanced gastric adenocarcinoma has been previously demonstrated in randomized clinical trials. However, real-world data regarding S-1 efficacy in Europ...

(This article belongs to the Special Issue Treatment of Gastric Cancer)
  • Review
  • Open Access
1 Citations
4,989 Views
31 Pages

Factors Influencing the Prescription of First-Line Treatment for Type 2 Diabetes Mellitus: A Systematic Review

  • Helena Silva-Moreira,
  • Fernando Moreira,
  • Ângelo Jesus,
  • Matilde Monteiro-Soares and
  • Paulo Santos

Background/Objectives: Understanding prescribing patterns for type 2 diabetes mellitus, a complex condition affecting over 10% of the global adult population, can optimise prescribing practices, guide policymakers in promoting evidence-based medicine...

(This article belongs to the Special Issue Early Intervention and Treatment Strategies for Diabetes)
  • Article
  • Open Access
16 Citations
5,223 Views
14 Pages

11 July 2022

(1) Background: The purpose was to systematically assess the impact of KRAS subtypes and co-mutations on responses of first-line treatment and outcomes by genetic classification in advanced KRAS mutant NSCLC. (2) Methods: Molecular pathology was conf...

(This article belongs to the Special Issue Target and Im-Oncology Therapeutic Approaches for Lung Cancer)
  • Article
  • Open Access
8 Citations
4,439 Views
11 Pages

Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes

  • Jiun-Long Wang,
  • Yi-Ting Tsai,
  • Ching-Heng Lin,
  • Abdulkadir Cidem and ,
  • Theresa Staniczek,
  • Gary Ro-Lin Chang,
  • Chih-Ching Yen,
  • Wei Chen,
  • Kowit-Yu Chong and
  • Chuan-Mu Chen
  • + 5 authors+ 0 author

21 August 2021

Lung cancer remains a challenge in daily practice. Chemotherapy is first considered for advanced lung adenocarcinoma bearing no active driver mutations. Maintaining drug efficacy and overcoming drug resistance are essential. This study aimed to explo...

(This article belongs to the Special Issue Metformin and Cancer)
  • Article
  • Open Access
3 Citations
2,156 Views
13 Pages

First-Line Therapy, Autologous Stem-Cell Transplantation, and Post-Transplantation Maintenance in the Management of Newly Diagnosed Mantle Cell Lymphoma

  • S. Bhella,
  • Norma P. Varela,
  • A. Aw,
  • C. Bredeson and ,
  • M. Cheung,
  • M. Crump,
  • G. Fraser,
  • S. Sajkowski and
  • T. Kouroukis
  • + 4 authors+ 0 author

1 December 2020

Background: In Ontario, no clearly defined standard of care for the management of mantle cell lymphoma (mcl) has been developed, and substantial variability from centre to centre is evident. This guidance document was prompted by the need to harmoniz...

  • Article
  • Open Access
7 Citations
3,010 Views
14 Pages

Factors Associated with Virological Failure in First-Line Antiretroviral Therapy in Patients Diagnosed with HIV-1 between 2010 and 2018 in Israel

  • Tali Wagner,
  • Itzchak Levy,
  • Daniel Elbirt,
  • Eduardo Shahar and ,
  • Karen Olshtain-Pops,
  • Hila Elinav,
  • Michal Chowers,
  • Valery Istomin,
  • Klaris Riesenberg and
  • Dan Turner
  • + 15 authors+ 10 authors

15 December 2023

Despite the progress in contemporary antiretroviral therapy (ART) and the continuous changes in treatment guidelines, virological failure (VF) is still an ongoing concern. The goal of this study was to assess factors related to VF after first-line AR...

(This article belongs to the Special Issue Advances in Research on HIV Drug Resistance and Other Determinants of Treatment Success: 2nd Edition)
  • Systematic Review
  • Open Access
1 Citations
4,948 Views
23 Pages

First-Line Systemic Therapy Outcomes in Western Population with Locally Advanced and Metastatic Gastric Cancer—A Systematic Review

  • Srujitha Marupuru,
  • Daniel Arku,
  • David R. Axon,
  • Lorenzo Villa-Zapata and ,
  • Mohsen Yaghoubi,
  • Marion K. Slack and
  • Terri Warholak
  • + 2 authors+ 0 author

Globally, gastric cancer is a major cause of cancer mortality, with a 5-year survival rate of 32% for locally advanced and metastatic gastric cancer (A/MCG). This systematic literature review summarized the clinical, safety, and humanistic outcomes a...

(This article belongs to the Section Gastrointestinal Disease)
  • Article
  • Open Access
7 Citations
4,197 Views
13 Pages

Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana

  • Ontlametse T. Bareng,
  • Sikhulile Moyo,
  • Mbatshi Mudanga,
  • Kagiso Sebina and ,
  • Catherine K. Koofhethile,
  • Wonderful T. Choga,
  • Natasha O. Moraka,
  • Dorcas Maruapula,
  • Irene Gobe and
  • Simani Gaseitsiwe
  • + 14 authors+ 9 authors

1 May 2024

We evaluated subsequent virologic outcomes in individuals experiencing low-level virem ia (LLV) on dolutegravir (DTG)-based first-line antiretroviral therapy (ART) in Botswana. We used a national dataset from 50,742 adults who initiated on DTG-based...

(This article belongs to the Special Issue HIV Reservoirs, Latency, and the Factors Responsible)
  • Article
  • Open Access
18 Citations
6,702 Views
21 Pages

High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia

  • Birkneh Tilahun Tadesse,
  • Natalie N. Kinloch,
  • Bemuluyigza Baraki,
  • Hope R. Lapointe and ,
  • Kyle D. Cobarrubias,
  • Mark A. Brockman,
  • Chanson J. Brumme,
  • Byron A. Foster,
  • Degu Jerene and
  • Zabrina L. Brumme
  • + 7 authors+ 2 authors

1 February 2018

Clinical monitoring of pediatric HIV treatment remains a major challenge in settings where drug resistance genotyping is not routinely available. As a result, our understanding of drug resistance, and its impact on subsequent therapeutic regimens ava...

(This article belongs to the Special Issue Homage to Mark Wainberg)
  • Article
  • Open Access
205 Views
21 Pages

27 October 2026

Background and Objectives: Relative dose intensity (RDI) reflects how closely chemotherapy follows the planned dose and schedule. We aimed to identify pretreatment factors associated with low RDI during first-line chemotherapy for epithelial ovarian...

(This article belongs to the Section Obstetrics and Gynecology)
  • Article
  • Open Access
3 Citations
3,488 Views
14 Pages

A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study

  • Arpit Agrawal,
  • M. V. Padma Srivastava,
  • Rohit Bhatia,
  • Vinay Goyal and ,
  • Mamta Bhushan Singh,
  • Venugopalan Y. Vishnu and
  • Anuj Prabhakar
  • + 2 authors+ 0 author

27 August 2023

Azathioprine (AZA) has demonstrated efficacy in multiple randomized control trials (RCTs) for Relapsing-Remitting Multiple Sclerosis (RRMS). However, we still need comparative real-world data with other first-line disease-modifying therapies (DMTs)....

(This article belongs to the Section Molecular and Cellular Neuroscience)
  • Review
  • Open Access
14 Citations
6,862 Views
14 Pages

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

  • Francesca Bonello,
  • Mariella Grasso,
  • Mattia D’Agostino,
  • Ivana Celeghini and ,
  • Alessia Castellino,
  • Mario Boccadoro and
  • Sara Bringhen
  • + 2 authors+ 0 author

29 December 2020

Elderly transplant-ineligible (NTE) patients represent the majority of patients affected by multiple myeloma (MM). Elderly patients are a highly heterogeneous population, with large variability in health and functional status. Thus, choosing their op...

(This article belongs to the Special Issue Multidrug Therapies Containing Monoclonal Antibodies for Multiple Myeloma)
  • Article
  • Open Access
9 Citations
6,004 Views
15 Pages

Background: Pembrolizumab monotherapy is the standard first-line treatment for metastatic non-small cell lung cancer (NSCLC) patients whose tumors express a PD-L1 tumor proportion score (TPS) of ≥50%. However, real-world data regarding its effecti...

(This article belongs to the Special Issue Advances in Lung Cancer: From Bench to Bedside)
  • Article
  • Open Access
38 Citations
5,444 Views
13 Pages

Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy

  • Mette T. Mouritzen,
  • Andreas Carus,
  • Morten Ladekarl,
  • Peter Meldgaard and ,
  • Anders W. M. Nielsen,
  • Anna Livbjerg,
  • Jacob W. Larsen,
  • Halla Skuladottir,
  • Charlotte Kristiansen and
  • Mette Pøhl
  • + 20 authors+ 15 authors

28 September 2021

Background The selection of patients with non-small cell lung cancer (NSCLC) for immune checkpoint inhibitor (ICI) treatment remains challenging. This real-world study aimed to compare the overall survival (OS) before and after the implementation of...

(This article belongs to the Special Issue Immunotherapy for Non-small Cell Lung Cancer)
  • Systematic Review
  • Open Access
3 Citations
3,772 Views
9 Pages

Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis

  • Yiqun Han,
  • Jiayu Wang,
  • Yun Wu,
  • Hangcheng Xu and ,
  • Yan Wang and
  • Binghe Xu
  • + 1 author+ 0 author

25 November 2022

To identify the advantageous therapy as the first-line treatment for patients with triple-negative breast cancer (TNBC). Randomized controlled trials were searched for on Medline, Embase, ClinicalTrials.gov, and the Cochrane Library between January 2...

(This article belongs to the Topic Immunotherapy and Targeted Therapy in Breast Cancer)
  • Article
  • Open Access
5 Citations
7,190 Views
14 Pages

Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib

  • Amanda Jane Williams Gibson,
  • Michelle Liane Dean,
  • Ishjot Litt,
  • Adrian Box and ,
  • Winson Y. Cheung and
  • Vishal Navani
  • + 1 author+ 0 author

26 April 2024

Introduction: The use of osimertinib in the first-line (1L) setting is an effective treatment option for sensitizing EGFR-mutations (EGFRm+) and has significantly altered the standard of care practice for EGFRm+ disease in Canada. Unfortunately, acqu...

(This article belongs to the Special Issue Clinical Management and Outcomes of Lung Cancer Patients)
  • Review
  • Open Access
3 Citations
9,111 Views
13 Pages

First-Line Treatments and Management of Metastatic Renal Cell Carcinoma Patients: An Italian Interdisciplinary Uro-Oncologic Group Algorithm

  • Francesco Bloise,
  • Fiorella Manfredi,
  • Luca Zatteri,
  • Giovanni Dima and ,
  • Chiara Carli,
  • Rosanna Di Vita,
  • Maria Olivieri,
  • Enrico Sammarco,
  • Marco Ferrari and
  • Federico Paolieri
  • + 14 authors+ 9 authors

2 June 2024

The treatment landscape for metastatic renal cell carcinoma (mRCC) has undergone significant transformations in recent years. The introduction of novel combination therapies involving tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors...

(This article belongs to the Section Cellular Pathology)
  • Article
  • Open Access
8 Citations
4,070 Views
16 Pages

Feasibility and Acceptability of a Strategy Deploying Multiple First-Line Artemisinin-Based Combination Therapies for Uncomplicated Malaria in the Health District of Kaya, Burkina Faso

  • Jean Moïse Tanga Kaboré,
  • Mohamadou Siribié,
  • Denise Hien,
  • Issiaka Soulama and ,
  • Nouhoun Barry,
  • Adama Baguiya,
  • Alfred B. Tiono,
  • Christian Burri,
  • André-Marie Tchouatieu and
  • Sodiomon B. Sirima
  • + 5 authors+ 0 author

(1) Background: Effective malaria case management relies on World Health Organization (WHO) recommended artemisinin-based combination therapies (ACTs), but partial resistance to artemisinin has emerged and is spreading, threatening malaria control an...

(This article belongs to the Special Issue Advances in Malaria Treatment and Prevention)
  • Article
  • Open Access
36 Citations
4,002 Views
14 Pages

Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab

  • Romain-David Seban,
  • Jean-Baptiste Assié,
  • Etienne Giroux-Leprieur,
  • Marie-Ange Massiani and ,
  • Michael Soussan,
  • Gérald Bonardel,
  • Christos Chouaid,
  • Margot Playe,
  • Lucas Goldfarb and
  • Laurence Champion
  • + 8 authors+ 3 authors

10 August 2020

Background: We aimed to assess the clinical utility of a previously published score combining the total metabolic tumor volume (TMTV) on baseline FDG-PET/CT and pretreatment derived from the neutrophils to lymphocytes ratio (dNLR) for prognostication...

(This article belongs to the Special Issue Advances in Lung Cancer Imaging and Therapy)
  • Article
  • Open Access
7 Citations
2,769 Views
17 Pages

Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study

  • Vittorio Del Fabro,
  • Mary Ann Di Giorgio,
  • Valerio Leotta,
  • Andrea Duminuco and ,
  • Claudia Bellofiore,
  • Uros Markovic,
  • Alessandra Romano,
  • Anna Bulla,
  • Angelo Curto Pelle and
  • Concetta Conticello
  • + 7 authors+ 2 authors

9 August 2023

Based on the results obtained in clinical trials, the use of the combination of lenalidomide and dexamethasone (Len/Dex) has become a potential therapeutic choice for newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transpl...

(This article belongs to the Section Cancer Therapy)
  • Article
  • Open Access
6 Citations
4,999 Views
14 Pages

Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study

  • Sneha Sura,
  • Manojkumar Bupathi,
  • Valerie Morris,
  • Paul Conkling and ,
  • Karen Todoroff,
  • Abhijeet Bhanegaonkar and
  • Chiemeka Ike
  • + 2 authors+ 0 author

Avelumab first-line maintenance (1LM) is approved for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who do not have disease progression after platinum-based chemotherapy (PBC). This retrospective study describes real-worl...

(This article belongs to the Section Genitourinary Oncology)
  • Article
  • Open Access
7 Citations
8,378 Views
14 Pages

First-Line Prescriptions and Effectiveness of Helicobacter pylori Eradication Treatment in Ireland over a 10-Year Period: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg)

  • Sinéad M. Smith,
  • Olga P. Nyssen,
  • Rebecca FitzGerald,
  • Thomas J. Butler and ,
  • Deirdre McNamara,
  • Asghar Qasim,
  • Conor Costigan,
  • Anna Cano-Catalá,
  • Pablo Parra and
  • Javier P. Gisbert
  • + 8 authors+ 3 authors

Background: Local audits of Helicobacter pylori (H. pylori) prescriptions and outcomes are necessary to assess guideline awareness among clinicians and treatment effectiveness. Aims: The aims were to investigate first-line prescriptions and effective...

  • Systematic Review
  • Open Access
5 Citations
3,785 Views
20 Pages

30 December 2022

Background: Immune checkpoint inhibitors (ICIs)-based therapy has recently been demonstrated to greatly ameliorate survival outcomes in advanced hepatocellular carcinoma (HCC). We aimed to evaluate clinical outcomes of ICIs-based monotherapy and comb...

(This article belongs to the Collection Advances in the Management of Hepatocellular Carcinoma)
  • Article
  • Open Access
6 Citations
3,285 Views
11 Pages

Comparison of Treatment Outcomes Between First-Line Chemotherapy With or Without Bevacizumab for Advanced Ovarian Clear Cell Carcinoma (Tohoku Gynecologic Cancer Unit: TGCU-RS001A Study)

  • Tadahiro Shoji,
  • Eriko Takatori,
  • Takayuki Nagasawa,
  • Masahiro Kagabu and ,
  • Tsukasa Baba,
  • Tatsuhiko Shigeto,
  • Yukiko Matsumura,
  • Dai Shimizu,
  • Yukihiro Terada and
  • Yoshihito Yokoyama
  • + 16 authors+ 11 authors

12 November 2024

Objective: The usefulness of bevacizumab (BEV) as first-line chemotherapy for advanced ovarian clear cell carcinoma (CCC) was retrospectively evaluated at Tohoku Gynecologic Cancer Unit institutions. Patients and Methods: A total of 81 patients (52 p...

(This article belongs to the Section Cancer Drug Development)
  • Article
  • Open Access
7 Citations
6,132 Views
15 Pages

9 January 2023

Aim: The key purposes of the treatment of metastatic malignancies are to extend survival and maintain the quality of life. Recently it has been emphasized in the scientific literature that the maintenance of maximal dose intensity is not always benef...

(This article belongs to the Section Gastrointestinal Oncology)
  • Article
  • Open Access
26 Citations
4,976 Views
11 Pages

Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model

  • Ezechiel Ngoufack Jagni Semengue,
  • Joseph Fokam,
  • Naomi-Karell Etame,
  • Evariste Molimbou and ,
  • Collins Ambe Chenwi,
  • Désiré Takou,
  • Leonella Mossiang,
  • Alain P. Meledie,
  • Bouba Yagai and
  • Alexis Ndjolo
  • + 24 authors+ 19 authors

21 December 2022

To ensure optimal prescribing practices in the dolutegravir-era in Cameroon, we compared first-line virological response (VR) under tenofovir + lamivudine + dolutegravir (TLD) according to prior exposure to tenofovir + lamivudine + efavirenz (TLE). A...

(This article belongs to the Section Viral Immunology, Vaccines, and Antivirals)
  • Review
  • Open Access
24 Citations
9,007 Views
16 Pages

PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis

  • Margarita Majem,
  • Manuel Cobo,
  • Dolores Isla,
  • Diego Marquez-Medina and ,
  • Delvys Rodriguez-Abreu,
  • Joaquín Casal-Rubio,
  • Teresa Moran-Bueno,
  • Reyes Bernabé-Caro,
  • Diego Pérez-Parente and
  • Luis Paz-Ares
  • + 7 authors+ 2 authors

26 March 2021

Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to...

(This article belongs to the Collection Biomarker for Non-small Cell Lung Cancer: From the Bench to the Bedside)
  • Article
  • Open Access
11 Citations
4,707 Views
13 Pages

Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

  • Valentina Danesi,
  • Ilaria Massa,
  • Flavia Foca,
  • Angelo Delmonte and ,
  • Lucio Crinò,
  • Giuseppe Bronte,
  • Maria Ragonesi,
  • Roberta Maltoni,
  • Silvia Manunta and
  • Mattia Altini
  • + 11 authors+ 6 authors

15 September 2022

Background: This study provides insights into the treatment use and outcomes of metastatic non-small cell lung cancer (NSCLC) patients in a real-world setting prior to and after the availability of immuno-oncology (IO) regimens in the first line (1L)...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Article
  • Open Access
3 Citations
3,235 Views
17 Pages

Gene Expression Pattern of ESPL1, PTTG1 and PTTG1IP Can Potentially Predict Response to TKI First-Line Treatment of Patients with Newly Diagnosed CML

  • Eva Christiani,
  • Nicole Naumann,
  • Christel Weiss,
  • Birgit Spiess and ,
  • Helga Kleiner,
  • Alice Fabarius,
  • Wolf-Karsten Hofmann,
  • Susanne Saussele and
  • Wolfgang Seifarth
  • + 4 authors+ 0 author

8 May 2023

The achievement of major molecular response (MMR, BCR::ABL1 ≤ 0.1% IS) within the first year of treatment with tyrosine kinase inhibitors (TKI) is a milestone in the therapeutic management of patients with newly diagnosed chronic myeloid leukemia (CM...

(This article belongs to the Section Cancer Biomarkers)

of 340